CFTRI to commercialise supplementary formulation for cancer therapy

30 July 2021 | News

CFTRI has a patent on the supplementary formulation named Encircle image credit- shutterstock image credit- shutterstock

CSIR-Central Food Technological Research Institute (CFTRI), Mysuru, is keen to commercialize one of its Indian patent entitled, “A supplementary formulation for cancer therapy and method for the preparation thereof" to interested parties.

Currently most of the commercial onco-food supplements are categorized to either prevent cancers or to increase immunity, proteins as a means of alleviating the side effects of treatments and therapies . This supplementary formulation opens up a new area in using food supplements to synergistically aid in current cancer treatments.

The patent is on a supplementary formulation, named Encircle, as a Ready-to-Eat or Ready-to-Drink supplement, to aid in cancer therapy.

This formulation with FDA/FSSAI approved ingredients, has been optimized using genetic algorithms, in ovarian cancer cell lines, with a cut-off survival of less than 40% and ensuring normal cells lines’ survival of more than 60%.

Expression of interest from Indian and Multi-nationals are invited for securing the license to manufacture and market the products in any countries of interest


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

© Copyright 2021. Nuffoods Spectrum. All Rights Reserved.
Website Design & Developed By : SCI Knowledge Interlinks